Myfortic (Mycophenolic Acid)

Mycophenolic acid inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides. Lymphocytes rely on this pathway for proliferation, so the drug selectively reduces T‑ and B‑cell growth, dampening the immune response that can lead to organ rejection.

The dosage of Myfortic is individualized based on the patient’s transplant type, weight, renal function, and concurrent immunosuppressive regimen. The prescribing clinician determines the appropriate dose and schedule, which may be adjusted over time according to therapeutic monitoring.

The safety of Myfortic in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and because it can cross the placenta and be excreted in breast milk, clinicians usually advise avoiding use unless the potential benefit justifies the potential risk to the fetus or infant.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and assistance with import documentation.

Myfortic (mycophenolic acid) is an antimetabolite that selectively inhibits lymphocyte proliferation, whereas calcineurin inhibitors such as tacrolimus act by blocking T‑cell activation. Myfortic is often used in combination with a calcineurin inhibitor and steroids to achieve synergistic immunosuppression while offering a different side‑effect profile, particularly less nephrotoxicity.

Myfortic delayed‑release tablets should be stored below 25 °C (77 °F) in their original packaging, protected from moisture and direct sunlight. Keeping the tablets in a dry, temperature‑controlled environment helps maintain their stability and ensures consistent drug release.

Myfortic is taken orally as a delayed‑release tablet, usually twice daily with food to improve tolerability and absorption. The tablet should be swallowed whole; it must not be crushed, chewed, or split, as this could alter the controlled‑release properties of the formulation.

The most serious risks include bone‑marrow suppression leading to leukopenia or anemia, severe or opportunistic infections, and potential liver injury. Rare but critical complications such as progressive multifocal leukoencephalopathy (PML) and increased malignancy risk have also been reported, requiring vigilant clinical monitoring.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients. It should be used with caution, or avoided, in individuals with severe renal or hepatic impairment, active uncontrolled infections, or those receiving live vaccines, as the drug can exacerbate these conditions.